The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...
The Rockville, Maryland-based company, which specializes in treatments for central nervous system diseases, has not yet disclosed pricing for its newest product. The backbone of Parkinson’s ...
A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback